Intravitreal dobesilate in the treatment of choroidal neovascularisation associated with age-related macular degeneration: Report of two cases

BMJ Case Reports

Volumn , Issue , 2012, Pages

  Cuevas, Pedro ^a   Outeiriño, Luis ^b   Azanza, Carlos ^b   Giménez Gallego, Guillermo ^c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Hospital de Día Pío XII   (Spain)

^c CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIHYDROXYBENZENESULFONIC ACID; BEVACIZUMAB; ETAMSYLATE; RANIBIZUMAB;

AGED; ARTICLE; BLURRED VISION; CASE REPORT; DISEASE ASSOCIATION; DRUG EFFICACY; DYSLEXIA; FEMALE; HUMAN; OCCULT CHOROIDAL NEOVASCULARISATION; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR LESION; VISUAL ACUITY; VISUAL FIELD DEFECT;

EID: 84867146650     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2012-006619     Document Type: Article

References (43)

1. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24(5 Suppl):S3-19.
2. Witkin AJ, Vuong LN, Srinivasan VJ, et al. High-speed ultrahigh resolution optical coherence tomography before and after ranibizumab forage-related macular degeneration. Ophthalmology 2009;116:956-63.
3. Van Leeuwen R, Klaver CC, Vingerling JR, et al. Epidemiology of age-related maculopathy: a review. Eur J Epidemiol 2003;18:845-54. (Pubitemid 37169020)
4. Rein DB, Zhang P, Wirth KE. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006;124:1754-60. (Pubitemid 44920172)
5. Lafaut BA, Bartz-Schmidt KU, Vanden Broecke C, et al. Clinicopathological correlation in exudative age-related macular degeneration: histological differentiation between classic and occult choroidal neovascularisation. Br J Ophthalmol 2000;84:239-43. (Pubitemid 30251676)
6. Giani A, Thanos A, Roh MI, et al. In vivo evaluation of laser-induced choroidal neovascularization using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2011;52:3880-7.
7. Fercher AF, Hitzenberger CK, Drexler W, et al. In vivo optical coherence tomography. Am J Ophthalmol 1993;116:113-14. (Pubitemid 23198501)
8. Swanson EA, Izatt JA, Hee MR, et al. In vivo retinal imaging by optical coherence tomography. Opt Lett 1993;18:1864-6.
9. Menke MN, Dabov S, Sturm V. Features of age-related macular degeneration assessed with three-dimensional Fourier-domain optical coherence tomography. Br J Ophthalmol 2008;92:1492-7.
10. Martin DE, Maguire MG, Ying GS, et al. CATT Research Group. Ranibizumab and bevacizumab for neovasular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
11. Jardeleza MS, Miller JW. Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin Ophthalmol 2009;24:87-92.
12. Ruiz de Almodovar C, Lambrechts D, Mazzone M, et al. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 2009;89:607-48.
13. Stewart MV. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc 2012;87:77-88.
14. Bakri SJ, McCannel CA, Edwards AO, et al. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:955-8.
15. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010;26:105-10.
16. Shimomura Y, Hirata A, Ishikawa S, et al. Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol 2009;247:1089-94.
17. Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995-1002.
18. Tremolada G, Del Turco C, Lattanzio R, et al. The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment. Exp Diabetes Res 2012;2012:728325.
19. Schultz GS, Grant MB. Neovascular growth factors. Eye (London) 1991;5:170-80.
20. Amin R, Puklin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 1994;35:3178-88. (Pubitemid 24241356)
21. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996;122:393-403. (Pubitemid 26300056)
22. Vinding R. Occurrence of drusen, pigmentary changes and exudative changes in the macula with reference to age-related macular degeneration. An epidemiological study of 1000 aged individuals. Acta Ophthalmol (Copenh) 1990;68:410-14.
23. Doyle SL, Campbell M, Ozaki E, et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med 2012;18:791-8
24. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006;58:353-63. (Pubitemid 44111070)
25. Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001;20:705-32. (Pubitemid 32918285)
26. Karaulanov EE, Böttcher RT, Niehrs C. A role for fibronectin-leucine-rich transmembrane cell-surface proteins in homotypic cell adhesion. EMBO Rep 2006;7:283-90.
27. Demos C, Bandyopadhyay M, Rohrer B. Identification of candidate genes for human retinal degeneration loci using differentially expressed genes from mouse photoreceptor dystrophy models. Mol Vis 2008;14:1639-49.
28. Ozawa Y, Nakao K, Kurihara T, et al. Roles of STAT3/SOCS3 pathway in regulating the visual function and ubiquitin-proteasome-dependent degradation of rhodopsin during retinal inflammation. J Biol Chem 2008;283:24561-70.
29. Bazan NG. Lipid signalling in neural plasticity, brain repair and neuroprotection. Mol Neurobiol 2005;32:89-103. (Pubitemid 41113211)
30. Bid HK, Oswald D, Li C, et al. Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12. PLoS One 2012;7:e35513.
31. Deo DD, Axelrad TW, Robert EG, et al. Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism. J Biol Chem 2002;277: 21237-45. (Pubitemid 34952260)
32. Bussolino F, Biffignandi P, Arese P. Platelet-activating factor - a powerful lipid autacoid possibly involved in microangiopathy. Acta Haematol 1986;75:129-40. (Pubitemid 16016166)
33. Brunet J, Farine JC, Garay RP, et al. In vitro antioxidant properties of calcium dobesilate. Fundam Clin Pharmacol 1998;12:205-12. (Pubitemid 28154611)
34. Cuevas P, Diaz-González D, Sánchez I, et al. Dobesilate inhibits the activation of signal transducer and activator of transcription (Stat)3 and the expresión of cyclin D1 and bcl-XL in glioma cells. Neurol Res 2006;28:127-30.
35. Cuevas P, Angulo J, Cuevas-Bourdier A, et al. Treatment of infiltrative basal cell carcinomas by inhibiting the fibroblast growth factor (FGF)-signal transducer and activator of transcription (STAT)-3 signalling pathways. J Cancer Sci Ther 2012 In press.
36. Fernández IS, Cuevas P, Angulo J, et al. Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors. J Biol Chem 2010;285:11714-29.
37. Angulo J, Peiró C, Romacho T, et al. Inhibition of vascular endothelial growth factor (VEGF)-inducedendothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. Eur J Pharmacol 2011;667:153-9.
38. Cuevas P, Angulo J, Giménez-Gallego G. Topical treatment of contact dermatitis by pine processionary caterpillar. BMJ Case Rep 2011;2011:bcr0620114351.
39. Allain H, Ramelet AA, Polard E, et al. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf 2004;27:649-60. (Pubitemid 38980450)
40. Haritoglou C, Gerss J, Sauerland C, et al. CALDIRET study group. Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2009;373:1364-71.
41. Clayton RA, Baker D, Lindon JC, et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA 2009;106:14728-33.
42. Arumugan M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011;473:174-80.
43. Cuevas P, Outeiriño LA, Angulo J, et al. Treatment of dry age-related macular degeneration with dobesilate. BMJ Case Rep 2012;10.1136/bcr.02.2012.5942, Published 22 June 2012.